Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs
- PMID: 18554744
- DOI: 10.1016/j.jhep.2008.05.008
Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs
Abstract
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
Comment on
-
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.Nat Med. 2008 Jan;14(1):25-7. doi: 10.1038/nm1698. Epub 2007 Dec 6. Nat Med. 2008. PMID: 18064037
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
